Boston Scientific recalls its LUX-Dx cardiac monitor

On 17 September 2026, Boston Scientific initiated a voluntary global recall of its LUX-Dx Insertable Cardiac Monitor System and associated software. The action follows delays identified in atrial fibrillation Burden Alerts used during patient monitoring.

The recall covers multiple versions of the LUX-Dx hardware and related software programs that can postpone detection alerts for atrial arrhythmias. The US Food and Drug Administration has taken enforcement interest in the measure, increasing regulatory scrutiny on the performance of the cardiac monitoring platform.

The company holds a market capitalization of approximately $63.6 billion and manufactures equipment for interventional procedures in cardiology and other medical specialties. Investors await future quarterly filings or communications from the US FDA to evaluate whether the remediation work will affect cardiology procedure volumes or segment revenue.